(Image: Associated Press)

No­var­tis scores its lat­est FDA OK — this time for a new sick­le cell dis­ease drug picked up in a $665M deal

No­var­tis’ de­ci­sion to buy Ok­la­homa-based biotech Se­lexys 3 years ago for up to $665 mil­lion has paid off with an FDA ap­proval to­day.

Blessed with the FDA’s break­through drug des­ig­na­tion for a speedy re­view, the phar­ma gi­ant has pinned down an ap­proval for crizan­l­izum­ab, a new ther­a­py de­signed to re­duce the fre­quen­cy of painful in­ci­dents of va­so-oc­clu­sive crises among sick­le cell dis­ease pa­tients 16 or old­er.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.